ArticleRSC advances2026
Injectable ε-poly-lysine/hyaluronic acid hydrogel for targeted prevention of cardiovascular implantable electronic device pocket infections.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular implantable electronic device (CIED) pocket infections represent a grave threat to the survival quality and life safety of patients with cardiovascular diseases, while also imposing a substantial economic burden on healthcare systems. However, the efficacy of current approaches employed for preventing CIED pocket infections remains suboptimal. In this study, an injectable antibacterial hydrogel was successfully constructed by physically crosslinking carboxyl groups on the surface of hyaluronic acid microspheres (HAG) with amino groups on poly-l-lysine (PLL). The developed HAG/PLL hydrogel exhibited not only non-toxicity toward L929 cells but also excellent cytocompatibility, accompanied by a low hemolysis rate when tested with red blood cells. Furthermore,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.